Amdoxovir

Amdoxovir

Clinical data
ATC code	none
Identifiers
IUPAC name [(2R,4R)-4-(2,6-diaminopurin-9-yl)-1,3-dioxolan-2-yl]methanol
CAS Number	145514-04-1  Y
PubChem CID	124088
ChemSpider	110576  Y
UNII	54I81H0M9C
KEGG	D02890  Y
ChEMBL	ChEMBL458876  Y
NIAID ChemDB	005431
CompTox Dashboard (EPA)	DTXSID801027435
Chemical and physical data
Formula	C9H12N6O3
Molar mass	252.234 g·mol−1
3D model (JSmol)	Interactive image
SMILES n2c1c(nc(nc1n(c2)[C@@H]3O[C@@H](OC3)CO)N)N
InChI InChI=1S/C9H12N6O3/c10-7-6-8(14-9(11)13-7)15(3-12-6)4-2-17-5(1-16)18-4/h3-5,16H,1-2H2,(H4,10,11,13,14)/t4-,5-/m1/s1 Y Key:RLAHNGKRJJEIJL-RFZPGFLSSA-N Y
(verify)

Amdoxovir is a pharmaceutical drug that has undergone research for the treatment of HIV/AIDS. It acts as a nucleoside reverse transcriptase inhibitor (NRTI). The drug was discovered by Raymond F. Schinazi (Emory University) and C.K. Chu (University of Georgia) and developed by RFS Pharma. ^[1]

Amdoxovir was in advanced Phase II clinical trials around 2010. ^[2] In 2013, a Phase II trial was terminated ^[3] and another was withdrawn before it started. ^[4] No further studies appear to have been done.

References

1. "Amdoxovir". AIDSmeds.com. January 13, 2009. Archived from the original on 2008-03-21. Retrieved March 21, 2008.
2. Murphy RL, Kivel NM, Zala C, Ochoa C, Tharnish P, Mathew J, Pascual ML, Schinazi RF (2010). "Antiviral activity and tolerability of amdoxovir with zidovudine in a randomized double-blind placebo-controlled study in HIV-1-infected individuals". Antivir Ther. 15 (2): 185–192. doi:10.3851/IMP1514. PMC   7733239 . PMID   20386073.
3. Clinical trial number NCT01737359 for "A Safety and Efficacy Study of Amdoxovir in HIV-1 Treatment-experienced Subjects" at ClinicalTrials.gov
4. Clinical trial number NCT01738555 for "A Safety and Efficacy Study of Amdoxovir in HIV-1 Treatment-experienced Subjects" at ClinicalTrials.gov